Transplant Medicine

Interim data on ISA(TX)247 presented

Published in Drug Week, October 18th, 2002

Randall Yatscoff, president and chief operating officer of Isotechnika presented interim results of an ongoing phase II clinical trial at the annual International Congress of the Transplantation Society in Miami, Florida that provided further confirmation of the therapeutic potential of ISA(TX)247, the company's lead drug to prevent organ rejection in transplantation.

ISA(TX)247 is being developed under a global collaboration agreement with Roche.

The phase II trial is a randomized, open label study of ISA(TX)247 and cyclosporine A in stable kidney transplant patients who are at least 6 months postoperative. The 12-week study is being conducted at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2002-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry